How long does it take for nintedanib/Vigat to take effect? u200bu200bDo patients need to be patient?

Nintedanib is a tyrosine kinase inhibitor primarily used to treat idiopathic pulmonary fibrosis (IPF), progressive phenotypic chronic fibrosing interstitial lung diseases (ILDs), and systemic sclerosis-related interstitial lung disease (SSc-ILD). The mechanism of action of this class of drugs is to slow down the progression of lung diseases and reduce the loss of lung function by inhibiting the fibrosis process in multiple biological pathways. Although nintedanib has shown significant clinical efficacy, patients need to understand that the effects of this drug are usually not immediate and the therapeutic effects may take some time to appear.

Usually, the therapeutic effect of nintedanib is not immediate, and patients often need to take it for a long time to see obvious effects. For lung diseases such as idiopathic pulmonary fibrosis, the development of the patient's condition is a gradual process, and it takes a period of time to improve or slow down the decline of lung function. The role of nintedanib is to delay the progression of the disease, not to cure it immediately, so patients must be patient. The effects of medications often take several months or longer to be felt. ForIPF patients, nintedanib can slow down the decline of lung function and improve quality of life, but this effect appears gradually.

For patients with chronic fibrosing interstitial lung disease and systemic sclerosis-related interstitial lung disease, the effect of nintedanib also takes a certain amount of time to show. Usually, immediate improvement may not be seen within the first three months of treatment. Therefore, patients and their families need to give the patient sufficient support and patience during the treatment process. In clinical practice, many patients can feel the relief of pulmonary symptoms after taking nintedanib for several months, such as coughing, shortness of breath and other symptoms, and the continued decline in lung function is significantly slowed down. This suggests that nintedanib plays a key role in slowing disease progression.

Reference materials:https://en.wikipedia.org/wiki/Nintedanib